Abbvie Announces Topline Results From The Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma; Etentamig Achieves 74% Orr And 60% Risk Reduction In Phase 3 Cervino Trial; Etentamig Demonstrates Low Rates Of Cytokine Release Syndrome And Fatal Infections; Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results To Be Presented Sept 23-26

AbbVie announced positive topline results from its Phase 3 CERVINO study for etentamig, an investigational multiple myeloma treatment, meeting both primary endpoints of objective response rate and progression-free survival. This strong clinical data suggests a potential new blockbuster drug for AbbVie, significantly impacting its future revenue streams and competitive position in the oncology market.

AbbVie announced highly positive Phase 3 results for etentamig, a BCMA-directed T-cell engager for relapsed/refractory multiple myeloma. The drug significantly improved objective response rate (74%) and progression-free survival (60% risk reduction) compared to standard therapies, with a manageable safety profile. This is a major catalyst for AbbVie, as etentamig could become a significant revenue driver in the competitive oncology space, offering a differentiated treatment option. Short-term, this news should boost investor confidence in ABBV; long-term, it positions the company for substantial market share in multiple myeloma, pending regulatory approval. The low rates of CRS and fatal infections, coupled with monthly dosing, present a key opportunity for market differentiation.